Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

797514

	registered interest
	date	29/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Thyroid Gland: Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what medicines NHS England has approved for patients with thyroid conditions
	tabling member constituency	Southampton, Itchen
	tabling member printed	Royston Smith
	uin	116477
	answer	answer is ministerial correction date of answer 07/12/2017 answer text <p><del class="ministerial">For unbranded generics the Government relies on completion to keep prices down which generally works well and has led to low prices of these medicines. We alert the Competition and Markets Authority (CMA) when we believe that competition does not work. In the case of liothyronine, the CMA is currently investigating Concordia’s potential abuse of its dominant position to overcharge the National Health Service for liothyronine.</del></p><p> </p><p><del class="ministerial">In primary care community pharmacies are incentivised to source products at the lowest possible cost by allowing them to retain the medicines margin (the difference between what the NHS reimburses a pharmacy for a product and how much the pharmacy purchases it for) up to £800 million in England. In secondary care, competitive tenders ensure value-for-money to the NHS.</del></p><p><ins class="ministerial"> <p><ins class="ministerial">NHS England is not responsible for approving medicines. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines and medical devices work and are acceptably safe. The National Institute for Health and Care Excellence makes recommendations for the National Health Service on whether medicines and other treatments represent a clinically and cost effective use of NHS resources.</ins></p><p><ins class="ministerial"><strong> </strong></ins></p><p><ins class="ministerial">A list of medicines licensed by the MHRA for the treatment of thyroid conditions is attached. The list is split into two sections because thyroid conditions can be split into either those associated with an overactive thyroid (hyperthyroidism), or an underactive thyroid (hypothyroidism). The list contains only those medicines licensed for overactive and underactive thyroid. It should be noted that not all of the medicines listed will be available on the market at any one time. </ins></p></ins></p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/12/2017 15:27:25 question first ministerially corrected 07/12/2017 18:20:31 answering member 4067 label Biography information for Steve Brine attachment 1 file name 2017 12 06 Thyroid medicines formatted.xls title List of thyroid medicines previous answer version 27995 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
	tabling member	4478 label Biography information for Royston Smith

802162

	registered interest
	date	06/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Radiology
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the NHS’ capacity to deliver 24-hour interventional radiology (image-guided surgery) services in each region.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	117849
	answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>The seven day services self-assessment survey completed by trusts in March 2017 included information on the availability of clinical interventions, including interventional radiology (IR), on a seven day basis for patients admitted to hospital in an emergency. The data showed that <ins class="ministerial">72.30%</ins><del class="ministerial">73.65%</del> of hospital trusts who responded to this survey (<del class="ministerial">109 </del> <ins class="ministerial">107</ins>out of 148 trusts) stated that IR was available for these patients seven days a week.</p><p> </p><p>Information on the twice yearly collection is available on the NHS England website at:</p><p><a href="https://www.england.nhs.uk/seven-day-hospital-services/progress" target="_blank">https://www.england.nhs.uk/seven-day-hospital-services/progress</a></p><p>National Health Service regions have access to this report and will be able to consider any variation.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 11/12/2017 17:57:45 question first ministerially corrected 26/01/2018 14:08:27 answering member 1542 label Biography information for Philip Dunne previous answer version 28792 answering member constituency Ludlow answering member printed Mr Philip Dunne answering member 1542 label Biography information for Philip Dunne
	tabling member	298 label Biography information for Steve McCabe

797397

	registered interest
	date	29/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Patients: Transport
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether (a) NHS England and (b) his Department plan to update guidance on the delivery of non-emergency patient transport.
	tabling member constituency	Oxford West and Abingdon
	tabling member printed	Layla Moran
	uin	116360
	answer	answer is ministerial correction date of answer 07/12/2017 answer text <p>The provision of appropriate National Health Service transport services is a matter for local NHS commissioners. There are no plans to review patient transport guidance.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/12/2017 15:29:18 answering member 4067 label Biography information for Steve Brine
	tabling member	4656 label Biography information for Layla Moran

797518

	registered interest
	date	29/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Liothyronine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that liothyronine will remain available on the NHS.
	tabling member constituency	Southampton, Itchen
	tabling member printed	Royston Smith
	uin	116481
	answer	answer is ministerial correction date of answer 07/12/2017 answer text <p>For unbranded generics the Government relies on completion to keep prices down which generally works well and has led to low prices of these medicines. We alert the Competition and Markets Authority (CMA) when we believe that competition does not work. In the case of liothyronine, the CMA is currently investigating Concordia’s potential abuse of its dominant position to overcharge the National Health Service for liothyronine.</p><p> </p><p>In primary care community pharmacies are incentivised to source products at the lowest possible cost by allowing them to retain the medicines margin (the difference between what the NHS reimburses a pharmacy for a product and how much the pharmacy purchases it for) up to £800 million in England. In secondary care, competitive tenders ensure value-for-money to the NHS.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 116470 116474 116477 116482 question first answered 07/12/2017 15:27:25 answering member 4067 label Biography information for Steve Brine
	tabling member	4478 label Biography information for Royston Smith

797519

	registered interest
	date	29/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Liothyronine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure liothyronine is competitively priced and provides value for money.
	tabling member constituency	Southampton, Itchen
	tabling member printed	Royston Smith
	uin	116482
	answer	answer is ministerial correction date of answer 07/12/2017 answer text <p>For unbranded generics the Government relies on completion to keep prices down which generally works well and has led to low prices of these medicines. We alert the Competition and Markets Authority (CMA) when we believe that competition does not work. In the case of liothyronine, the CMA is currently investigating Concordia’s potential abuse of its dominant position to overcharge the National Health Service for liothyronine.</p><p> </p><p>In primary care community pharmacies are incentivised to source products at the lowest possible cost by allowing them to retain the medicines margin (the difference between what the NHS reimburses a pharmacy for a product and how much the pharmacy purchases it for) up to £800 million in England. In secondary care, competitive tenders ensure value-for-money to the NHS.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 116470 116474 116477 116481 question first answered 07/12/2017 15:27:25 answering member 4067 label Biography information for Steve Brine
	tabling member	4478 label Biography information for Royston Smith

797897

	registered interest
	date	30/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pharmacy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what estimate he has made of the number of (a) GP appointments and (b) A&E admissions that could have been treated by a pharmacy in 2016.
	tabling member constituency	Mid Dorset and North Poole
	tabling member printed	Michael Tomlinson
	uin	116804
	answer	answer is ministerial correction date of answer 08/12/2017 answer text <p>The Department does not hold an estimate of this for this timeframe.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/12/2017 14:59:08 answering member 4067 label Biography information for Steve Brine
	tabling member	4497 label Biography information for Michael Tomlinson

798638

	registered interest
	date	01/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Leukaemia: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when the ATIR treatment for people with leukaemia will be available on the NHS.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	117032
	answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>The National Institute for Health and Care Excellence (NICE) has been asked to develop technology appraisal guidance on the use of ATIR101 to support haematopoietic stem cell transplantation using partially mismatched (haploidentical) family members as donors, for the treatment of some blood cancers. NICE’s appraisal is being scheduled in line with a clinical trial that is expected to complete in 2020.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/12/2017 17:46:50 answering member 4067 label Biography information for Steve Brine
	tabling member	4131 label Biography information for Jim Shannon

798639

	registered interest
	date	01/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prostate Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when the SelectMDx urine test for prostate cancer will be made available on the NHS.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	117033
	answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>The future availability of any new or novel tests on the National Health Service, such as the SelectMDx test for prostate cancer, would be subject to large scale clinical trials demonstrating the safety and efficacy of the diagnostic approach and subsequent assessments of its cost effectiveness for routine use.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/12/2017 17:47:34 answering member 4067 label Biography information for Steve Brine
	tabling member	4131 label Biography information for Jim Shannon

798640

	registered interest
	date	01/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cold Sores: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what guidance his Department issues on the treatment of cold sores.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	117034
	answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>Guidance on the treatment of cold sores is available on the NHS Choices website.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/12/2017 17:41:13 answering member 4067 label Biography information for Steve Brine
	tabling member	4131 label Biography information for Jim Shannon

798641

	registered interest
	date	01/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Scarlet Fever
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment his Department made of trends in the instances of scarlet fever in the UK.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	117035
	answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>Public Health England recently undertook a comprehensive assessment of longitudinal trends in scarlet fever in England and Wales in light of the elevation in scarlet fever disease incidence, noted from 2014 onwards. This identified that the population rate in 2016 (33 cases per 100,000 population) was the highest seen since 1967. The study also identified a rise in hospitalisations during this period of elevated incidence, although the majority were discharged the same day. Weekly notifications during the 2017 seasonal peak of activity showed a slight drop compared to the previous year.</p><p> </p><p>The assessment is available to view here:</p><p><a href="http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30693-X/fulltext?elsca1=tlpr" target="_blank">www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30693-X/fulltext?elsca1=tlpr</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/12/2017 17:43:00 answering member 4067 label Biography information for Steve Brine
	tabling member	4131 label Biography information for Jim Shannon